Talk:Dz13

Page contents not supported in other languages.
From Wikipedia, the free encyclopedia

Protected edit request on 5 December 2019[edit]

Change: under ”Mechanism of action”; include: It has been reported off-target effects of Dz13, not related to the inactivation of c-Jun [1][2][3]

Change: under “References”; include: [1] [2] [3]

Change: under “Investigations”, before the sentence “A series of investigations”; include: Six of Khachigian's research articles have been retracted and one corrected due to unresolved concerns over missing or manipulated data. [4] [5] [6]

Change: under “Investigations”, end of paragraph; include: “This conclusion has been challenged”.[7]

Reason for change: important to include more information from another point of view. Moroks (talk) 13:28, 5 December 2019 (UTC)[reply]

 Not done for now: please establish a consensus for this alteration before using the {{edit protected}} template. — Martin (MSGJ · talk) 22:33, 5 December 2019 (UTC)[reply]

References

  1. ^ a b Rivory, L. et al (2006) The DNAzymes Rs6, Dz13, and DzF have potent biologic effects independent of catalytic activity. Oligonucleotides 16, 297–312.
  2. ^ a b Goodchild, A. et al (2007) Cytotoxic G-rich oligode-oxynucleotides: putative protein targets and required sequence motif. Nucleic Acids Res. 35, 4562–4572.
  3. ^ a b Gozar, M.M. et al (2008) Dz13, a DNAzyme Targeting c-jun, Induces Off-Target Cytotoxicity in Endothelial Cells with Features of Nonapoptotic Programmed Cell Death. Oligonucleotides 18(3), 257-268.
  4. ^ http://retractionwatch.com/2013/08/12/aussie-university-halts-trials-of-skin-cancer-drug-whose-developer-has-four-retractions/
  5. ^ https://retractionwatch.com/2013/11/04/jbc-issues-correction-for-paper-by-khachigian-who-has-had-four-others-retracted/
  6. ^ http://retractionwatch.com/2019/01/14/an-australian-university-cleared-a-cancer-researcher-of-misconduct-hes-now-retracted-six-papers/
  7. ^ https://www.abc.net.au/news/2019-10-17/unsw-skin-cancer-levon-khachigian-allegations-and-retractions/11585768

Protected edit request on 10 December 2019[edit]

Change: Under the headline “Mechanism of action”; include as the third paragraph:

Oligonucleotides such as Dz13 may be used with carriers such as cationic polymers for improved cellular delivery and efficacy.[1] Dz13 in such polymers inhibits tumor cell proliferation and migration by suppressing levels of c-Jun and MMPs,[2] reduces H1N1 and H7N2 viral replication and increases survival of mice infected with influenza A[3] and suppresses c-Jun and solid tumor growth in biomimetic nanoballs.[4] Dz13 has also been used in dermal drug delivery systems for enhanced skin penetration of DNAzyme.[5]

Under “References”; include:

[1] [2] [3] [4] [5]

Reason for change:

Provides critical information on Dz13 from different laboratories.


Moroks suggested on 5 December 2019 to “Change: under “Investigations”, before the sentence “A series of investigations”; include: Six of Khachigian's research articles have been retracted and one corrected due to unresolved concerns over missing or manipulated data. [4] [5] [6]”. This sentence should not be included since it is neither relevant nor factual as explained below.

Reasons for not inserting Moroks’ proposed sentence:

(a) Only one (1) of the 6 retracted articles relates to Dz13.[6] This is the “2010 paper” already noted in the existing first sentence “In 2013, trials of Dz13 …”. It is mischievous to refer to the 5 other papers on this page as these do not relate to Dz13; (b) None of the publisher retraction notices for any of these 6 research articles refer to manipulated data;[7] (c) Although data manipulation was initially alleged, the independent expert panels investigating this article found genuine error or honest oversight, not deliberate or intentional conduct.[8] [9]

— Preceding unsigned comment added by HansonPeabody (talk • contribs) 21:17, 10 December 2019 (UTC) HansonPeabody (talk) 21:22, 10 December 2019 (UTC)HansonPeabody (talk) 21:23, 10 December 2019 (UTC)HansonPeabody (talk) 21:24, 10 December 2019 (UTC)[reply]

HansonPeabody (talk) 21:31, 10 December 2019 (UTC)[reply]

References

  1. ^ a b Kynova, R. et al (2014) Enhancing nucleic acid delivery, insights from the cationic phospholipid carriers. Current Pharmaceutical Biotechnology 15(9), 806-13.
  2. ^ a b Yang. J. et al (2019) Inhibition of proliferation and migration of tumor cells through phenylboronic acid-functionalized polyamidoamine-mediated delivery of a therapeutic DNAzyme Dz13. International Journal of Nanomedicine 14, 6371–6385.
  3. ^ a b Zhang, Z. et al (2017) DNAzymes Dz13 target the c-jun possess antiviral activity against influenza A viruses. Microbial Pathogenesis 103, 155-161.
  4. ^ a b Kim, M.-G. et al (2015) Biomimetic DNA nanoballs for oligonucleotide delivery. Biomaterials 62, 155-163.
  5. ^ a b Marquardt, K. et al (2015) Development of a protective dermal drug delivery system for therapeutic DNAzymes. International Journal of Pharmaceutics 479, 150-158.
  6. ^ http://retractiondatabase.org/RetractionSearch.aspx#?auth%3dKhachigian%252c%2bLevon%2bM
  7. ^ http://retractiondatabase.org/RetractionSearch.aspx#?auth%3dKhachigian%252c%2bLevon%2bM
  8. ^ https://retractionwatch.com/2015/12/15/cancer-researcher-cleared-of-misconduct-inquiry-finds-genuine-error-or-honest-oversight/
  9. ^ https://www.theaustralian.com.au/higher-education/unsw-clears-levon-khachigian-of-all-allegations-of-research-misconduct/news-story/f707b2c14b5cc251a4db5fcbe5778002

Protected edit request on 10 December 2019 (signed)[edit]

Change: Under the headline “Mechanism of action”; include as the third paragraph:

Oligonucleotides such as Dz13 may be used with carriers such as cationic polymers for improved cellular delivery and efficacy.[1] Dz13 in such polymers inhibits tumor cell proliferation and migration by suppressing levels of c-Jun and MMPs,[2] reduces H1N1 and H7N2 viral replication and increases survival of mice infected with influenza A[3] and suppresses c-Jun and solid tumor growth in biomimetic nanoballs.[4] Dz13 has also been used in dermal drug delivery systems for enhanced skin penetration of DNAzyme.[5]

Under “References”; include:

[1] [2] [3] [4] [5]

Reason for change:

Provides critical information on Dz13 from different laboratories.


Moroks suggested on 5 December 2019 to “Change: under “Investigations”, before the sentence “A series of investigations”; include: Six of Khachigian's research articles have been retracted and one corrected due to unresolved concerns over missing or manipulated data. [4] [5] [6]”. This sentence should not be included since it is neither relevant nor factual as explained below.

Reasons for not inserting Moroks’ proposed sentence:

(a) Only one (1) of the 6 retracted articles relates to Dz13.[6] This is the “2010 paper” already noted in the existing first sentence “In 2013, trials of Dz13 …”. It is mischievous to refer to the 5 other papers on this page as these do not relate to Dz13; (b) None of the publisher retraction notices for any of these 6 research articles refer to manipulated data;[7] (c) Although data manipulation was initially alleged, the independent expert panels investigating this article found genuine error or honest oversight, not deliberate or intentional conduct.[8] [9] HansonPeabody (talk) 21:33, 10 December 2019 (UTC) HansonPeabody (talk) 21:33, 10 December 2019 (UTC)[reply]

References

  1. ^ a b Kynova, R. et al (2014) Enhancing nucleic acid delivery, insights from the cationic phospholipid carriers. Current Pharmaceutical Biotechnology 15(9), 806-13.
  2. ^ a b Yang. J. et al (2019) Inhibition of proliferation and migration of tumor cells through phenylboronic acid-functionalized polyamidoamine-mediated delivery of a therapeutic DNAzyme Dz13. International Journal of Nanomedicine 14, 6371–6385.
  3. ^ a b Zhang, Z. et al (2017) DNAzymes Dz13 target the c-jun possess antiviral activity against influenza A viruses. Microbial Pathogenesis 103, 155-161.
  4. ^ a b Kim, M.-G. et al (2015) Biomimetic DNA nanoballs for oligonucleotide delivery. Biomaterials 62, 155-163.
  5. ^ a b Marquardt, K. et al (2015) Development of a protective dermal drug delivery system for therapeutic DNAzymes. International Journal of Pharmaceutics 479, 150-158.
  6. ^ http://retractiondatabase.org/RetractionSearch.aspx#?auth%3dKhachigian%252c%2bLevon%2bM
  7. ^ http://retractiondatabase.org/RetractionSearch.aspx#?auth%3dKhachigian%252c%2bLevon%2bM
  8. ^ https://retractionwatch.com/2015/12/15/cancer-researcher-cleared-of-misconduct-inquiry-finds-genuine-error-or-honest-oversight/
  9. ^ https://www.theaustralian.com.au/higher-education/unsw-clears-levon-khachigian-of-all-allegations-of-research-misconduct/news-story/f707b2c14b5cc251a4db5fcbe5778002
Retrieved from "https://en.wikipedia.org/w/index.php?title=Talk:Dz13&oldid=1214429785"